Arkolith/Insider Trading/SPRY/Form 4

Karas Eric

Chief Commercial OfficerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Jun 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$250K
Net Open-Market Flow
-$250K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)25K$1.50$38K37K
Jun 12, 2026Sell(S)25K$10.00$250K12K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)25K—$0520K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001951287-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML